García TJ, Lacy NRM, Vega MME, Boeta ÁL

Language: Spanish
References: 14
Page: 379-380
PDF size: 92.20 Kb.

Text Extraction

No abstract.

REFERENCES

1. Ziemer M, Atypical fibroxanthoma, J Dtsch Dermatol Ges 2012; 10:537-50.

2. Calvo I, Del Castillo JL y Losa PM, Fibroxantoma atípico, Rev Esp CirugOral y Maxilofac 2017; 39(4):250-2.

3. Anderson HL y Joseph AK, A pilot feasibility study of a rare skin tumordatabase, Dermatol Surg 2007; 33(6):693-6.

4. Love WE, Schmitt AR y Bordeaux JS, Management of unusual cutaneousmalignancies: atypical fibroxanthoma, malignant fibrous histiocytoma,sebaceous carcinoma, extramammary Paget disease, DermatolClin 2011; 29(2):201.

5. Seavolt M y McCall M, Atypical fibroxanthoma: review of the literatureand summary of 13 patients treated with mohs micrographicsurgery, Dermatol Surg 2006; 32(3):435-41.

6. Sakamoto A, Oda Y, Itakura E et al., Immunoexpression of ultravioletphotoproducts and p53 mutation analysis in atypical fibroxanthomaand superficial malignant fibrous histiocytoma, Mod Pathol 2001;14:581-8.

7. Koch M, Freundl AJ, Agaimy A et al., Atypical fibroxanthoma: histologicaldiagnosis, immunohistochemical markers and concepts of therapy,Anticancer Res 2015; 35(11):5717-35.

8. Hussein MRA, Atypical fibroxanthoma: new insights, Expert Rev AnticancerTher 2014; 14(9):1075-88.

9. Bugatti L y Filosa G, Dermatoscopic features of cutaneous atypicalfibroxanthoma: three cases, Clin Exp Dermatol 2009; 34(8):e898-900.

10. Weedon D, Tumors and tumor-like proliferations of fibrous and relatedtissues. En Weedon’s Skin Pathology, 3ª ed., Elsevier Limited, 2010,p. 809.

11. Mirza B y Weedon D, Atypical fibroxanthoma: a clinicopathologicalstudy of 89 cases, Australas J Dermatol 2005; 46(4):235-8.

12. Withers AHJ, Brougham NDL, Barber RM et al., Atypical fibroxanthomaand malignant fibrous histiocytoma, J Plast Reconstr Aesthet Surg2011; 64(11):e273-8.

13. Winchester D, Lehman J, Tello T et al., Undifferentiated pleomorphicsarcoma: factors predictive of adverse outcomes, J Am Acad Dermatol2018; 79(5):853-9.

14. Ang GC, Roenigk RK, Otley CC et al., More than 2 decades of treatingatypical fibroxanthoma at mayo clinic: what have we learned from 91patients?, Dermatol Surg 2009; 35:765-72.